Literature DB >> 16605130

IgE regulation of mast cell survival and function.

Toshiaki Kawakami1, Jiro Kitaura, Wenbin Xiao, Yuko Kawakami.   

Abstract

Traditionally, it is thought that IgE binding to mast cells via the high-affinity receptor (FcepsilonRI) is simply a passive 'sensitization' step prior to activation by receptor aggregation or cross-linking with multivalent antigen or other cross-linking agents. However, in addition to receptor up-regulation, recent studies have shown that monomeric IgE can induce survival and other activation events including increased histamine content, degranulation, leukotriene release, receptor internalization, adhesion, migration and DNA synthesis. Various IgE molecules exhibit a vast spectrum of heterogeneity: the highly cytokinergic (HC) group of IgEs at an extreme end of the spectrum can induce survival and other activation events very efficiently, whereas poorly cytokinergic (PC) IgEs at the other end can do so less efficiently. All the IgEs tested appear to be capable of inducing receptor aggregation with HC IgEs having a higher capacity to do so than PC IgEs. HC IgEs can promote the production and secretion of various cytokines including the one(s) that can sustain survival in an autocrine and paracrine mechanism. Consistent with receptor aggregation induced by monomeric IgE, other means of receptor aggregation, e.g. IgE+antigen and IgE+anti-IgE, can also induce survival and other events in unique ranges of stimulation intensity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16605130

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  8 in total

Review 1.  New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action?

Authors:  Margaret E Walker; Julianne K Hatfield; Melissa A Brown
Journal:  Biochim Biophys Acta       Date:  2011-02-25

2.  Pathogenic role of mast cells in experimental eosinophilic esophagitis.

Authors:  Rituraj Niranjan; Parm Mavi; Madhavi Rayapudi; Scott Dynda; Anil Mishra
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-04-18       Impact factor: 4.052

3.  Endogenous suppression of mast cell development and survival by IL-4 and IL-10.

Authors:  Kelly Speiran; Daniel P Bailey; Josephine Fernando; Matthew Macey; Brian Barnstein; Motunrayo Kolawole; Dana Curley; Stephanie S Watowich; Peter J Murray; Carole Oskeritzian; John J Ryan
Journal:  J Leukoc Biol       Date:  2009-02-19       Impact factor: 4.962

4.  Paracrine IL-33 stimulation enhances lipopolysaccharide-mediated macrophage activation.

Authors:  Tatsukuni Ohno; Keisuke Oboki; Hideaki Morita; Naoki Kajiwara; Ken Arae; Shizuko Tanaka; Masako Ikeda; Motoyasu Iikura; Taishin Akiyama; Jun-ichiro Inoue; Kenji Matsumoto; Katsuko Sudo; Miyuki Azuma; Ko Okumura; Thomas Kamradt; Hirohisa Saito; Susumu Nakae
Journal:  PLoS One       Date:  2011-04-11       Impact factor: 3.240

5.  Fluorogen-activating proteins provide tunable labeling densities for tracking FcεRI independent of IgE.

Authors:  Samantha L Schwartz; Qi Yan; Cheryl A Telmer; Keith A Lidke; Marcel P Bruchez; Diane S Lidke
Journal:  ACS Chem Biol       Date:  2014-11-24       Impact factor: 5.100

Review 6.  Total IgE as a Marker for Chronic Spontaneous Urticaria.

Authors:  Sabine Altrichter; Jie Shen Fok; Qingqing Jiao; Pavel Kolkhir; Polina Pyatilova; Sherezade Moñino Romero; Jörg Scheffel; Frank Siebenhaar; Carolin Steinert; Dorothea Terhorst-Molawi; Yi Kui Xiang; Martin K Church; Marcus Maurer
Journal:  Allergy Asthma Immunol Res       Date:  2021-03       Impact factor: 5.764

Review 7.  Mast Cells as Important Regulators in Autoimmunity and Cancer Development.

Authors:  Christine N Noto; Stella G Hoft; Richard J DiPaolo
Journal:  Front Cell Dev Biol       Date:  2021-10-12

Review 8.  Mast cells as a potential prognostic marker in prostate cancer.

Authors:  Gianluigi Taverna; Guido Giusti; Mauro Seveso; Rodolfo Hurle; Piergiuseppe Colombo; Sanja Stifter; Fabio Grizzi
Journal:  Dis Markers       Date:  2013-11-11       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.